Over time, this can create a cycle of escalating doses, worsening sensitivity, and declining function without meaningful healing (33,35,36)
Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Always start microdosing after getting a prescription from your doctor and have regular follow-ups for continuous monitoring and care
J.SeoW.KimD
What it proposes instead is a complementary role for people with elevated triglycerides, insulin resistance, or metabolic syndrome, with a qualified provider evaluating the full lipid panel, cardiovascular risk profile, and medical history before treatment begins
Herbst EA, Paglialunga S, Gerling C, Whitfield J, Mukai K, Chabowski A, Heigenhauser GJ, Spriet LL, Holloway GP